U.S. Markets closed

Bear of the Day: Barrick Gold (ABX)

Kevin Cook
1 / 2

Halozyme Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Halozyme Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

I've written about large-cap gold miners like Barrick Gold (ABX) many times over the years for the Bear of the Day feature.

The steadily eroding earnings outlook for these companies is no surprise, even as the price of gold rallies.

Since a summer of 2016 peak for the yellow metal near $1375, it has fallen to support at $1125 and rallied back to $1350.

Meanwhile, Barrick Gold shares have fallen over 40% from $23 to $13, and the Market Vectors Gold Miners ETF (GDX) fell 26%.

One look at the earnings picture for ABX from the Zacks proprietary Price & Consensus chart will explain why...

What you see is EPS on the left-hand scale with each colored line representing the changes in annual estimates over time.

The right hand scale is the stock price, showing a steady decline as earnings growth never really showed up the past two years.

The top line isn't much better with this year's expected $8.03 billion revenue haul posting as a 4% decline over last year -- and this when the average price of gold is holding higher than 2017 and looking technically robust.

The Monetary Myth of the Barbarous Relic

The cost of producing an ounce of gold is over $800 for the majority of miners. And one element besides the high cost of production that always hurts the miners is past hedging.

If a miner has obligations via futures, options, or OTC forward contracts to sell gold at say $1300, $1200, or even $1100, then rising spot prices don't have the direct margin leverage one would think.

And I remain bearish on gold, believing nothing in monetary policy or the inflation outlook will much help it get back to $1500 and above.

In October I wrote a special report for Zacks Confidential titled The Monetary Myth of Gold where I explained why the barbarous relic was soon doomed in the high-tech age of fiat currencies, digital finance, and artificial intelligence.

Instead, I recommended investors put their money into real economic growth stories like NVIDIA (NVDA), Alibaba (BABA), and Edwards Lifesciences (EW).

That report has my detailed thesis on all the dynamics for gold, including the dollar, inflation, and the relativity of currency fluctuations in a global economy.

I even suggested that cryptocurrencies like Bitcoin were proving the digital era would offer more important economic innovations to extract than anything we could dig from the ground.

Barrick Gold may indeed be worth something near $15 billion but I wouldn't pay that now for cash flow that is headed the wrong direction, and could be for a while.

Disclosure: I own shares of NVDA and BABA for Zacks TAZR Trader and shares of EW for Zacks Healthcare Innovators.

Breaking News: Cryptocurrencies Now Bigger than Visa

The total market cap of all cryptos recently surpassed $700 billion – more than a 3,800% increase in the previous 12 months. They’re now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.

Zacks’ has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.

Click here to access these stocks. >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
VANECK-GOLD MNR (GDX): ETF Research Reports
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
Alibaba Group Holding Limited (BABA) : Free Stock Analysis Report
Barrick Gold Corporation (ABX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research